Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex

Transfusion and Apheresis Science

Volumn 39, Issue 1, 2008, Pages 21-28

  Zhang, Cheng ^a   Chen, Xinghua ^a   Zhang, Xi ^a   Gao, Lei ^a   Kong, Peiyan ^a   Wang, Qingyu ^a   Peng, Xiangui ^a   Liu, Hong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autologous peripheral hematopoetic stem cell transplantation (Auto PBSCT); CD34+ cells; Hematological malignancies; Mobilization; Recombinant human interleukin 11 (rhIL 11)

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; RECOMBINANT INTERLEUKIN 11; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CD34 SELECTION; CHILD; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; SEX DIFFERENCE; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 47349130267     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.05.011     Document Type: Article

References (40)

1. Wright D.E., Wagers A.J., Gulati A.P., Johnson F.L., and Weissman I.L. Physiological migration of hematopoietic stem and progenitor cells. Science 294 5548 (2001) 1933-1936
2. Abkowitz J.L., Robinson A.E., Kale S., Long M.W., and Chen. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102 (2003) 1249-1253
3. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 13 10 (1995) 2547-2555
4. Moskowitz C.H., Glassman J.R., Wuest D., et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4 2 (1998) 311-316
5. Carral A., de la Rubia J., Martín G., et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 27 1 (2003) 5-12
6. Ergene U., Çaǧirgan S., Pehlivan M., Yilmaz M., and Tombuloǧlu M. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). Transfus Apher Sci 36 1 (2007) 23-29
7. + cells in elderly patients (>/=70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 120 3 (2003) 413-423
8. Carral A., de la Rubia J., Martín G., et al. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant 29 10 (2002) 825-832
9. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leukemia Lymphoma 44 5 (2003) 815-820
10. Reddy R.L. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci 32 1 (2005) 63-72
11. Filshie R.J. Cytokines in haemopoietic progenitor mobilization for peripheral blood stem cell transplantation. Curr Pharm Design 8 5 (2002) 379-394
12. Nowrousian M.R., Waschke S., Bojko P., et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 14 Suppl. (2003) i29-i36
13. Rahman J.E., and Maclellan W.R. Fundamentals of stem cell mobilization for the heart: Prospects for treating heart disease. Curr Opin Invest Drugs 7 9 (2006) 799-805
14. Jansen J., Thompson J.M., Dugan M.J., et al. Peripheral blood cell progenitor cell transplantation. Thera Apheresis 6 (2002) 5-14
15. + cells with a low cell content. Bone Marrow Transplant 19 11 (1997) 1103-1110
16. Stewart D.A., Guo D., Morris D., et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 23 2 (1999) 111-117
17. Jowitt S.N., Chang J., Morgenstern G.R., et al. Factors which affect the CFU-GM content of the peripheral blood haemopoietic progenitor cell harvests in patients with acute myeloid leukaemia. Br J Haematol 100 4 (1998) 688-694
18. Linker C.A., Ries C.A., Damon L.E., et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 6 1 (2000) 50-57
19. Watts M.J., Sullivan A.M., Jamieson E., et al. Progenitor cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor cell quantity and quality and factors predictive for these parameters in 101 pre-treated patients with malignant lymphoma. J Clin Oncol 15 2 (1997) 535-546
20. McQuaker I.G., Haynes A.P., Stainer C., Anderson S., and Russell N.H. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 100 3 (1998) 612-613
21. Richman C.M., Weiner R.S., and Yankee R.S. Increase in circulating stem cells following chemotherapy in man. Blood 47 6 (1976) 1031-1039
22. Juttner C.A., To L.B., and Ho J.Q.K. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 20 1 (1988) 40-42
23. Socinski M.A., Cannistra S.A., Elias A., et al. Granulocyte-Macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1 (1988) 1194-1198
24. Kroger N., Renges H., Kruger W., et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulated factor (filgrastism) for stem cell mobilization in healthy donors for allogeneic transplantation. Brit J Haematol 111 (2000) 761-765
25. Weaver C.H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD 34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86 10 (1995) 3961-3969
26. Ikeda K., Kozuka T., and Harada M. Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci 31 3 (2004) 245-259
27. Pettengell R., Testa N.G., Swindell R., Crowther D., and Dexter T.M. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 82 7 (1993) 2239-2248
28. Bernstein S.H., Nademanee A.P., Vose J.M., et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 91 9 (1998) 3509-3517
29. McKay P.J., Murphy J.A., Camerson S., et al. Iron overload and liver dysfunction after allogenenic and autologous bone marrow transplantation. Bone Marrow Transplant 17 1 (1996) 63-66
30. Borbolla J.R., Lopez-Hernandez M.A., DeDiego J., et al. Use of interleukin-11 after autologous stem cell transplant: report of three cases and a very brief review of the literature. Haematologica 86 (2001) 891-892
31. Lei W., Liang J., Chen W.G., Ma X.Z., Xu M., and Du L.L. Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia. Zhonghua Zhong Liu Za Zhi 28 7 (2006) 542-544
32. Bhatia M., Davenport V., and Cairo M.S. The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leukemia Lymphoma 48 1 (2007) 9-15
33. Gordon M.S., McCaskill-Stevens W.J., Battiato L.A., et al. A phase I trial of recombinant human interleukin-11 in women with breast cancer receiving chemotherapy. Blood 87 9 (1996) 3615-3624
34. Isaacs C., Robert N.J., Bailey F.A., et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15 11 (1997) 3368-3377
35. Tepler I., Elias L., Smith J.W., et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87 9 (1996) 3607-3614
36. Meng F.Y., Jiang Z.J., Yi Z.S., et al. Study of murine hematopoietic stem/progenitor cell mobilized by recombinant human interleukin 11 combination with granulocyte-colony stimulating factor. Zhonghua Xue Ye Xue Za Zhi 24 5 (2003) 225-227
37. Reynolds C.H. Clinical efficacy of rhIL-11. Oncology (Williston Park) 14 9 Suppl. 8 (2000) 32-40
38. Goldman S., Davenport V., Reaman G., et al. Combination of rhIL-11CSF enhances platelet and myeloid recovery following ifosfamide, carboplatin, and etoposide (ICE) chemotherapy in children with solid tumors: rhIL-11 is well tolerated at double the adult recommended dose. Exp Hematol 25 (1997) 786a
39. de la Rubia J., Arbona C., de Arriba F., et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 42 1 (2002) 4-9
40. McLeod B.C., Sniecinski D., Ciavarella D., et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 39 3 (1999) 282-288